Processa Pharmaceuticals, Inc. (PCSA) Earnings History
Annual and quarterly earnings data from 2010 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export PCSA earnings history in CSV or JSON format
Free sign-in required to download data
Processa Pharmaceuticals, Inc. (PCSA) Earnings Overview
As of March 1, 2026, Processa Pharmaceuticals, Inc. (PCSA) reported trailing twelve-month net income of -$13M, reflecting +0.5% year-over-year growth. The company earned $-272.14 per diluted share over the past four quarters.
Looking at the long-term picture, PCSA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$160,000 in fiscal 2010.
Processa Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), PCSA has comparable earnings metrics. Compare PCSA vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$12M | -6.6% | -$12M | $-3.87 | - | - |
| 2023 | -$11M | +59.4% | -$11M | $-8.48 | - | - |
| 2022 | -$27M | -140.0% | -$28M | $-1.70 | - | - |
| 2021 | -$11M | +40.0% | -$12M | $-14.92 | - | - |
| 2020 | -$19M | -467.0% | -$15M | $-50.77 | - | - |
| 2019 | -$3M | +10.8% | -$4M | $-12.17 | - | - |
| 2018 | -$4M | -102.8% | -$5M | $-14.20 | - | - |
| 2017 | -$2M | -452.5% | -$2M | $-8.00 | - | - |
| 2016 | $-335,982 | +90.0% | -$2M | $-29.89 | -6719.6% | -38430.4% |
| 2015 | -$3M | +25.9% | $3M | $-298.40 | -2957.2% | 2372.6% |
See PCSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCSA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PCSA vs AGIO
See how PCSA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PCSA growing earnings?
PCSA EPS of $-272.14 reflects slowing growth at +0.5%, below the 5-year CAGR of N/A. TTM net income is $-13M. Expansion rate has moderated.
What are PCSA's profit margins?
Processa Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are PCSA's earnings?
PCSA earnings data spans 2010-2024. The current earnings trend is +0.5% YoY. Historical data enables comparison across business cycles.